<DOC>
	<DOCNO>NCT02583191</DOCNO>
	<brief_summary>The purpose study show feasibility ( efficacy safety ) Rivaroxaban treatment VTE cancer patient comparison standard treatment low molecular weight heparin ( LMWH ) . Tumor patient active cancer newly diagnose thromboembolic event randomise receive either Rivaroxaban standard treatment low-molecular heparin .</brief_summary>
	<brief_title>Rivaroxaban Treatment Venous Thromboembolism ( VTE ) Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Newly diagnose objectively confirm acute venous thromboembolism Active malignancy Life expectancy least 6 month PerformanceStatus accord Karnofsky Performance Scale ≥ 70 % Patient 's compliance geographical situation allow adequate follow platelet ≥ 100.000 /μl , INR &lt; 1.5 , PTT &lt; 40 sec . write informed consent patient prior procedure connection study male female patient age least 18 year therapeutic anticoagulation &gt; 96 hour prior study treatment know allergic reaction study drug substance include therein know condition associate high risk bleeding , know history hemorrhagic diathesis acute clinically relevant bleeding last 2 week history spontaneous major/cerebral bleed history heparin induce thrombocytopenia II pregnant breastfeed woman . Women childbearing potential must negative pregnancy test perform &lt; 7 day prior start treatment severe renal insufficiency ( GFR &lt; 30 ml/min ) liver disease coagulation impairment , include Child B C cirrhosis acute medical illness treatment underlie cancer experimental therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>